new shares continue to break, and the new ecology is also gradually changing. (from April 25 to 29) a total of 8 new shares were listed, of which 4 were broken on the first day, all of which were new shares on the science and innovation board
After the May Day holiday, there are only two trading days this week. According to the current arrangement, if there is no change (from May 5 to 6), a total of 3 new shares are applied for, including 2 on GEM and 1 on Beizheng.
this week’s new 3 shares
The issue price of two new shares has been disclosed this week.
The average p / E ratio of biological industry is 20.97 times that of the last 10 months, which is lower than that of the industry. The issuing price of Prius is 46.8 yuan, and the issuing P / E ratio is 48.75 times, which is lower than the industry’s average dynamic P / E ratio of 60.56 times in the latest month
Prius was founded in 2013 and its main business is to provide SMO services for clinical research and development of pharmaceutical companies, medical device companies and some health-related products outside China after the issuance, Prius will be the first A-share listed SMO (site management organization) listed company
In the golden age of the rapid development of SMO industry, Prius, relying on its core competitiveness in the fields of project management ability, project implementation experience and the coverage of clinical trial institutions, promoted its own performance to maintain a sustained growth trend. In 2021, Prius’s operating revenue was 503 million yuan, a year-on-year increase of 50.01%; The net profit was 57.769 million yuan, a year-on-year increase of 63.58%.
By the end of 2021, among the newly listed PD-1 / PD-L1 mAb new drug products in China, Prius (including the first listed PD-1 mAb new drug product in China) accounted for 58.33%; In 2021, the proportion of Prius undertaking the double antibody clinical trial project in China reached 32.43%; In the field of viral hepatitis, Prius has undertaken 57.89% of the 19 new viral hepatitis products newly listed in China since 2016.
Prius IPO raised 702 million yuan for clinical trial site expansion project, big data analysis platform project, headquarters base construction project and supplementary working capital.
In terms of equity structure, on the eve of IPO, Lai Chunbao controlled 53.78% of the voting rights of the issuer through direct or indirect shareholding and concerted action agreement, and was the actual controller of Pryce. In addition, there is no lack of star capital in the listed equity structure, in which Hillhouse Siheng holds 2% equity of Prius.
Zhongke Jiangnan, which plans to raise 652 million yuan, is a leading supplier of intelligent financial comprehensive solutions in China and a major participant in the electronic payment standard of treasury funds of the people’s Bank of China and the Ministry of finance. Based on the relevant technologies of electronic treasury payment and financial information construction, the company provides financial, financial, security, service and other overall solutions to financial departments at all levels, financial institutions, administrative institutions and other customers. The main products and services include electronic payment solutions, integrated financial budget management solutions, financial service platforms of budget units, operation and maintenance services, etc.
The net profits of Zhongke Jiangnan from 2019 to 2021 were 711564 million yuan, 125 million yuan and 156 million yuan respectively. In addition, combined with the company’s orders in hand, project implementation and actual operation, Zhongke Jiangnan predicts that in the first half of 2022, the operating revenue will be 340 million yuan to 380 million yuan, with a year-on-year increase of 13.66% to 27.03%, and the net profit will be 45-65 million yuan, with a year-on-year change of – 12.84% to 25.89%.
It is worth noting that Zhongke Jiangnan is a company controlled by Grg Banking Equipment Co.Ltd(002152) ( Grg Banking Equipment Co.Ltd(002152) ), which is a state-owned holding enterprise. Prior to IPO, Grg Banking Equipment Co.Ltd(002152) directly held 46% of the shares of the company, and the actual controller of the company was Guangzhou SASAC. Through its subordinate enterprise Guangzhou Radio Group, Grg Banking Equipment Co.Ltd(002152) 50.01% of the shares were held by Grg Banking Equipment Co.Ltd(002152) and 46% of the shares of Zhongke Jiangnan were indirectly controlled.
last week, 14 IPOs held a meeting
In terms of the IPO meeting, last week (April to 29), a total of 17 enterprises launched at the meeting, including 5 on the main board, 6 on the gem, 4 on the science and innovation board and 2 on the Beijing stock exchange. Finally, 14 had a meeting, one was rejected, one was suspended and one cancelled the audit.
The room service originally scheduled for the meeting on April 28 withdrew the materials on the eve of the meeting. The room service is also the fourth enterprise to “cancel the order” on the eve of the conference this year.
Shangfang service, founded in 2001, is a property management enterprise focusing on non residential property management business. At the beginning of its establishment, it was called “Xingxiang property”. After two equity transfers, the company changed its current name in 2014.
The room service was officially listed on the new third board on June 8, 2017, and the company officially delisted and left on December 10, 2018. Unlike many property enterprises that rely on the parent company of real estate enterprises, the housing service focuses on the field of public property and commercial property.
According to the prospectus, from 2018 to the first half of 2021, the room service achieved operating revenue of 592 million yuan, 722 million yuan, 818 million yuan and 464 million yuan respectively; The net profits were 356341 million yuan, 47.957 million yuan, 722217 million yuan and 368341 million yuan respectively. As of the first half of 2021, the area under management of the company was 173178 million square meters.
the only IPO rejected last week came from frog pump, which is a high-tech enterprise specializing in the R & D, production and sales of well submersible pumps. Frog pump plans to raise 630 million yuan for the construction project of intelligent chemical plant and R & D center with an annual output of 1.5 million water pumps and supplement working capital
At the meeting of the development and examination committee held last week, the development and Examination Committee asked frog pump to explain whether the revenue growth trend is reasonable in combination with the market and comparable companies in the same industry; Explain the company’s internal control over dealer management, purchase, sales and inventory, whether it can effectively understand the realization of dealer inventory and terminal sales, and whether the distribution income is truly realized; Explain the reason and rationality of the high proportion of illegal dealers, whether there are third-party collection, cash collection and payment with dealers of unincorporated entities, and whether they comply with industry practices.
Type a new calendar
5
Dayu Biology (889000) is a high-tech enterprise mainly engaged in the R & D, production, sales and service of mixed feed additives, additive premixed feed and single feed. Since its establishment, the company has established a technology R & D system combining industry, University and research, and continuously improved animal organ function, animal immunity and feed utilization efficiency in the direction of promoting growth, improving quality and replacing antibiotics.
may 6
Zhongke Jiangnan (301153) is an information technology service provider focusing on data security. Its main business is to provide electronic solutions for banks, government departments, enterprises and institutions. The products and services provided by the company are mainly divided into three categories: electronic security solutions, financial information management solutions, operation and maintenance services, etc.
Prius (301257) is an SMO company, whose main business is to provide on-site management services for clinical trials. By providing excellent clinical research coordinator Cr (Clinical Research Coordinator), assist researchers in performing non-medical judgment transactional work in clinical trials, ensure that the clinical trial process complies with the provisions of GCP and research protocol, and effectively communicate with the sponsor, hospital institutions and cro to promote the standardization of clinical trials.
